Skip to content

CMS Establishes HCPCS code for Ultromics EchoGo® Heart Failure, Accelerating Access to Precision HFpEF Detection

HCPCS code C9786 can be used for billing AI-enabled EchoGo® Heart Failure to aid the detection of HFpEF.

[Oxford, July 5th, 2023] - Ultromics, a leading health technology company advancing a novel approach for detecting heart failure and its phenotypes, announced today the assignment of a new outpatient code by the Centers for Medicare and Medicaid Services (CMS), for its flagship product, EchoGo® Heart Failure.

CMS established a new HCPCS code (C9786) in the Hospital Outpatient Prospective Payment System (OPPS) for Ultromics’ technology with the following descriptor designated for Medicare beneficiaries receiving the service in the hospital outpatient setting. The new HCPCS code went into effect on July 1st, 2023.

EchoGo® Heart Failure is the first US Food and Drug Administration (FDA) cleared platform for detecting Heart Failure with Preserved Ejection Fraction (HFpEF), using a single view of an echocardiogram. The platform has the potential to catch disease earlier and get more patients on the pathway to treatment.

CMS's position is supported by clinical evidence presented at the American Society of Echocardiography (ASE) 2023 Scientific Sessions, demonstrating the effectiveness of EchoGo® Heart Failure for the detection of HFpEF. Combined with Breakthrough Device Designation by the FDA, providers can have trust and confidence in Ultromics' ability to deliver effective and innovative solutions for heart failure care.

"This is a major milestone and will enable hospitals to accelerate the adoption of EchoGo® Heart Failure, to improve detection of HFpEF within their systems” said Dr. Ross Upton, CEO and Founder of Ultromics. “Given the prevalence of HFpEF, this is a significant development toward recognizing and detecting a heavily underdiagnosed condition.”

As many as 50 percent of heart failure cases in the United States are HFpEF.

EchoGo® Heart Failure is an AI-enabled device that automatically analyses patient scans from a minimally invasive echocardiogram. It contains an AI algorithm, that once activated, screens for HFpEF. The technology can automate the detection process for a complex clinical syndrome where diagnosis is often uncertain, resulting in more patients getting a correct and expeditious diagnosis.

The assigned HCPCS code (C9786) brings Ultromics one step closer to transforming cardiovascular care and solidifying its position as a leader in the field. With these codes in place, it opens the door for the adoption of EchoGo® Heart Failure to empower healthcare providers with cutting-edge technology and the potential to improve patient outcomes.

EchoGo® Heart Failure received FDA clearance in the USA in December 2022. The device is available in the United States.

Providers interested in using EchoGo® Heart Failure may register their interest here.

For more information, including the code's official long descriptor and status indicator, click here (Table 8).

Curious about upcoming research and innovation?

Sign up to hear about the latest news.